HEPATITIS-C GENOTYPING BY DIRECT SEQUENCING OF THE PRODUCT FROM THE ROCHE AMPLICOR TEST - METHODOLOGY AND APPLICATION TO A SOUTH AUSTRALIANPOPULATION

Citation
J. Holland et al., HEPATITIS-C GENOTYPING BY DIRECT SEQUENCING OF THE PRODUCT FROM THE ROCHE AMPLICOR TEST - METHODOLOGY AND APPLICATION TO A SOUTH AUSTRALIANPOPULATION, Pathology, 30(2), 1998, pp. 192-195
Citations number
29
Categorie Soggetti
Pathology
Journal title
ISSN journal
00313025
Volume
30
Issue
2
Year of publication
1998
Pages
192 - 195
Database
ISI
SICI code
0031-3025(1998)30:2<192:HGBDSO>2.0.ZU;2-I
Abstract
The Roche AMPLICOR RT-PCR amplifies a 244 nucleotide sequence within t he 5' non coding region (5'NCR) of the viral genome and is a widely us ed commercial test for the qualitative determination of hepatitis C RN A from sera. This paper describes a routine procedure for the purifica tion of the PCR product, and its use in automated DNA sequencing, for determining the genotype of hepatitis C virus (HCV) isolates. Direct s equencing of the purified product was possible for 86% of samples, whi lst 14% required additional amplification using a nested PCR method in order to read the resulting electropherogram. This method of genotypi ng is considerably less expensive than currently available commercial kits, and is convenient for the increasing number of laboratories that have access to automated DNA sequencers. The highly conserved nature of the 5'NCR limited differentiation of types and subtypes to an exten t comparable to commercial HCV typing methods. Using this method on av ailable laboratory samples and on patients about to commence interfero n therapy, we found a predominance of genotype 1 (59%) and 3a (31%). A nalysis of data on the interferon patients showed the median length of time from first exposure to diagnosis to be significantly longer for patients with genotype 1 than genotype 3a.